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Bardet-Biedl syndrome (BBS) is a genetically heterogeneous disorder, the primary features of which include obesity,
retinal dystrophy, polydactyly, hypogenitalism, learning difficulties, and renal malformations. Conventional linkage
and positional cloning have led to the mapping of six BBS loci in the human genome, four of which (BBS1, BBS2,
BBS4, and BBS6) have been cloned. Despite these advances, the protein sequences of the known BBS genes have
provided little or no insight into their function. To delineate functionally important regions in BBS2, we performed
phylogenetic and genomic studies in which we used the human and zebrafish BBS2 peptide sequences to search
dbEST and the translation of the draft human genome. We identified two novel genes that we initially named
“BBS2L1” and “BBS2L2” and that exhibit modest similarity with two discrete, overlapping regions of BBS2. In
the present study, we demonstrate that BBS2L1 mutations cause BBS, thereby defining a novel locus for this
syndrome, BBS7, whereas BBS2L2 has been shown independently to be BBS1. The motif-based identification of
a novel BBS locus has enabled us to define a potential functional domain that is present in three of the five known
BBS proteins and, therefore, is likely to be important in the pathogenesis of this complex syndrome.
Introduction
Bardet-Biedl syndrome (BBS [MIM 209900]) is a pleio-
tropic disorder of likely developmental origin, in which
the primary features of retinal dystrophy, obesity, poly-
dactyly, gonadal, and renal malformations, as well as
developmental delay, manifest with substantial inter- and
intrafamilial variability (Beales et al. 1999). Despite an
initial expectation that BBS might represent a single-
locus disorder, linkage studies established substantial ge-
netic heterogeneity in BBS. To date, six loci have been
mapped in the human genome with evidence for at least
one more unmapped locus (Kwitek-Black et al. 1993;
Leppert et al. 1994; Sheffield et al. 1994; Carmi et al.
1995; Young et al. 1999; Katsanis et al. 2000; Beales et
al. 2001). Furthermore, the identification of the first three
BBS genes revealed increased complexity in the mode of
trait transmission, given that, in some families, three
mutations at two loci were shown to be required for
pathogenesis (Katsanis et al. 2001a, 2002; Badano and
Katsanis 2002).
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The identification of the first three BBS genes (BBS2,
BBS4, and BBS6) provided limited information about
their cellular role (Katsanis et al. 2000; Slavotinek et al.
2000; Mykytyn et al. 2001; Nishimura et al. 2001).
BBS6 shows significant similarity to group II chaperon-
ins (Stone et al. 2000), whereas the BBS4 sequence con-
tains fewer functional clues, as it exhibits modest sim-
ilarity to TPR-containing proteins such as O-linked
N-acetylglucosamine (O-GlcNAc) transferases from dif-
ferent species (Nishimura et al. 2001; Wells et al. 2001;
Katsanis et al. 2001b). By contrast, BBS2 encodes a
721–amino acid protein of unknown function and, with
the exception of a putative coiled-coil domain between
residues 332–365, computational analyses have not re-
vealed any other knownmotifs. Furthermore, alignment
of the human BBS2 peptide sequence to its orthologs from
various species has provided limited information about
functionally important residues because of the substan-
tial conservation across the entire BBS2 protein family.
We hypothesized that identifying more distantly re-
lated members of the BBS2 family might facilitate the
recognition of critical domains, as these likely would be
subjected to elevated evolutionary pressure. We report
here the identification of two novel genes with moderate
similarity toBBS2, whichwe initially termed “BBS2L1”
and “BBS2L2” (BBS2-like 1 and 2).We also demonstrate
that mutations in BBS2L1 cause BBS, thereby defining
a novel locus for this syndrome, BBS7. During the
course of this work, the second BBS2 paralog, BBS2L2,
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Figure 1 Mapping and genomic structure of BBS2L1 and its murine ortholog. The position and size of each exon of the human and
mouse transcript are shown (black boxes). In the human transcript, two different splice variants of exon 18 are shown. In the short isoform,
the 124-bp–long exon 18 is contiguous with an additional 417-bp 3′ UTR (box with diagonal dashes), whereas, in the long isoform, this exon
is spliced with a new 726-bp exon that encodes an additional 44 residues and a different 3′ UTR (dotted box). We subsequently termed this
locus “BBS7” because of the presence of pathogenic mutations that segregated with BBS.
was shown independently to be BBS1, the major BBS
locus, and to share modest similarity over 192 amino
acids to BBS2 (Mykytyn et al. 2002). These data point
to the first direct link between three of the five known
BBS genes, by virtue of the presence of a novel protein
motif whose disruptionmay commonly result in the same
clinical phenotype.
Patients and Methods
Families with Bardet-Biedl Syndrome
Individuals with Bardet-Biedl syndrome were ascer-
tained on the basis of criteria established elsewhere (Beales
et al. 1999). For all kindreds, interviewswere conducted,
and a genealogy was constructed. With informed con-
sent, one of us (R.A.L.) obtained and reviewed all avail-
able medical records to verify phenotypic features and
secure the diagnosis.
Genetic Analyses
DNAwas extracted from venous lymphocytes; families
were genotyped with published markers from the respec-
tive critical intervals, and haplotypes were constructed. A
genome screen with the 10-cM Linkage Map Set (Perkin
Elmer) was applied to suitable pedigrees; alleles were an-
alyzed and LOD scores were tabulated as described else-
where (Katsanis et al. 2000).Marker order, heterozygosity
values, and relative distances were obtained from the Ge-
nome Database and by BLAT analysis of the June 2001
version of the draft human genome sequence (build 30).
Genomic Structure of BBS7 and Mutation Screening
We aligned the cDNA sequence of bothBBS7 isoforms
to genomic sequence by BLAT and established the pres-
ence of 19 exons. We extracted 100–300 bp of sequence
flanking each coding exon and designed amplicons that
span both exons and intronic splice junctions as described
by Katsanis et al. (2000). Amplified PCR products from
patients, relatives, and unrelated but ethnically matched
control individuals were purified with the Exo-SAP clean-
up kit (USB) and sequenced with dye-primer chemistry,
using an ABI 377 automated sequencer (Applied Bio-
systems). We aligned the resulting sequences and eval-
uated mutations with the Sequencher sequence align-
ment program (Gene codes).
Expression Studies
To determine the size and tissue distribution of BBS7,
we amplified a 217-bp fragment from the 3′ UTR and
probed a northern blot that contained polyA mRNA
from 12 adult human tissues. To validate the presence
of two alternative 3′ end isoforms and to investigate the
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Figure 2 Expression profile of BBS7. A, Northern blotting of a human 3′ UTR probe showing an ∼2.7-kb species expressed in low-to-
moderate levels in multiple human tissues. B, RT-PCR analysis of the two alternatively spliced isoforms in 17 adult and 8 fetal tissues. The
short isoform (sBBS2L1) is ubiquitously expressed, whereas the long isoform (lBBS2L1) is expressed in numerous, but not all, tissues.
tissue distribution of each mRNA species, we amplified
a 298-bp 3′ UTR fragment of the short BBS7 isoform
and a 314-bp 3′ UTR fragment of the long BBS7 isoform
from 17 adult and 8 fetal tissues.
Results
Identification of Two Distant Paralogs of BBS2
To identify proteins with limited similarity to BBS2,
we used the human and zebrafish BBS2 peptide sequence
to search the conceptual translation of the human subset
of the EST database (dbEST). We identified numerous
ESTs with 25%–40% similarity to BBS2, which we as-
sembled into five discrete contigs, B2lc1–5. Alignment of
the consensus nucleotide sequence of each contig indi-
cated that B2lc1 and B2lc3 were 99.8% identical across
an overlapping region of 124 bp and were, therefore,
integrated into a single 1,048-bp sequence. However, the
absence of a bona fide start methionine or a stop codon
implied that our sequence represented a partial cDNA.
Figure 3 Mutations in BBS7 associated with BBS. A, Recessive inheritance in BBS7. The sole affected individual, –05, in consanguineous
family KK26 harbors a homozygous 4-bp deletion in exon 7 that is predicted to lead to premature termination in exon 9 (K237fsX296), thereby
abolishing ∼64% of the wild-type protein. Likewise, in two unrelated pedigrees (AR25 and AR395), all patients are homozygous for an H323R
allele. Individuals unavailable for collection are shown with dashes. B, Complex inheritance in BBS7. Consanguineous pedigree AR69 harbors
a homozygous T211I missense mutation in BBS7 and a heterozygous E234K mutation in BBS1. All patients carry all three mutant alleles, and
genetic analyses across BBS1 indicate that this family is unlikely to carry other mutations at that locus, since affected individuals –04 and –05
have inherited different paternal chromosomes. Note that asymptomatic sibling –03 has identical BBS1 haplotypes to patient –04, including
the heterozygous E234K mutation.

Badano et al.: Identification of BBS7 655
Figure 4 A potential domain shared between multiple BBS proteins. A, Schematic representation of the region of overlap between the
three proteins. The region of homology between BBS1 and BBS2 is shown in orange; the homology between BBS2 and BBS7 only is shown in
red, whereas the area of overlap among all three proteins is depicted in light blue. Numbers correspond to amino acid residues; the predicted
b-propeller, as well as the mutations in BBS1 and BBS7, are also shown (scale is approximate). Note that the potential BBS1 triallelic mutation
E234K maps in a region shared between BBS1 and BBS2. B, Local alignment of BBS2 orthologs with homologous regions in BBS7 and BBS1.
The positions of the BBS7 mutations are also shown; the threonine 211 residue is completely conserved and forms part of this potential domain,
whereas the 4-bp deletion at the lysine 237 residue of BBS7 abolishes most of the region shared uniquely with BBS2. hsp Homo sapiens; mm
p Mus musculus; rn p Rattus norvegicus; dr p Danio rerio; and ce p Caenorhabditis elegans.
To obtain the full-length transcript, we performed ad-
ditional BLAST searches of dbEST and the human draft
genomic sequence coupled with exon prediction analy-
ses. Combining additional EST sequence with genomic
information, we assembled a single contig of 2,580 nu-
cleotides (GenBank accession number AF521643). Given
the strong Kozak consensus around the first methionine,
with a stop codon 21 bp upstream and an AATAAA poly-
adenylation signal 12 bp before the 3′ end of our se-
quence, we concluded that we had likely determined the
full-length sequence of this novel gene. We named this
transcript “BBS2L1,” as it exhibits 42.5% similarity be-
tween residues 147 and 398 of BBS2; it contains a single
672–amino acid ORF from bp 149–2164, encoded by
19 exons, and maps to chromosome 4q27 (fig. 1).
Contigs Bl2c2, 4, and 5 did not align directly to each
other. However, BLAT analysis of human draft genomic
sequence (Kent 2002) indicated that all three contigs
map within 20 kb of each other and likely represent
different regions of the same transcript, whichwe termed
“BBS2L2.” During the progress of these studies, a se-
quence identical to BBS2L2 was reported to harbor
pathogenic mutations in patients with BBS and shown
to correspond to the major BBS locus, BBS1 (Mykytyn
et al. 2002).
Identification of the Murine Ortholog of BBS2L1
To extend our evolutionary studies of the BBS2 pro-
tein family, we deduced the sequence of the mouse
Bbs2l1 ortholog by using the human BBS2L1 nucleotide
sequence to query the mouse subdivision of dbEST, as
well as the mouse draft genomic sequence. We identified
14 mouse ESTs that exhibited 82%–93% identity with
BBS2L1 at the nucleotide level. Assembly of all murine
cDNA sequences and alignment to BBS2L1 revealed
three independent contigs that corresponded to different,
nonoverlapping regions of the human gene: a 706-bp 5′
contig, a middle 996-bp contig, and a 597-bp 3′ contig.
Further EST assembly bridged the middle and 3′ contigs,
leaving an ∼900-bp gap. To obtain the full-length mouse
cDNA, we amplified this gap by RT-PCR and sequenced
the resulting products. The final assembled 2,594-bp
murine sequence encodes a 716–amino acid peptide that
exhibits 94.1% similarity and 91.5% identity to the hu-
man BBS2L1 protein. This suggested that we had iden-
tified the ortholog of BBS2L1, which we termed
“Bbs2l1” (GenBank accession number AF521645).
BBS2L1 Utilizes Differentially Expressed Alternative 3′
Termini
To confirm that we had identified the full-length se-
quence of BBS2L1 and to investigate its pattern of ex-
pression, we performed northern blotting and RT-PCR
on adult and fetal human tissues. We detected a BBS2L1
message of the expected size in a wide range of tissues
(fig. 2a). However, when we compared the sequence of
BBS2L1 with its murine ortholog, we observed that the
mouse transcript had a different 3′ end, and we consid-
ered the possibility of alternative splicing. Using the
unique mouse 3′ end to search dbEST and genomic se-
quence, we determined a putative alternative 3′ end for
BBS2L1, which yields an mRNA that encodes an ad-
ditional 44 residues and terminates in a discrete 3′ UTR.
To ensure that this sequence was not a computational
artifact, we performed RT-PCR and determined that this
additional BBS2L1 sequence was present in multiple tis-
sues but with a pattern distinct from the previously rec-
ognized expression pattern of BBS2L1 (fig. 2b).
BBS2L1 Defines a Novel BBS Locus, BBS7
BBS2L1 maps to 4q27, a region of the genome not
associated previously with any known BBS locus. How-
ever, given the similarity between BBS2L1 and BBS2, we
hypothesized that BBS2L1 mutations may also cause
BBS, a concept reinforced by the identification of patho-
genic alterations in BBS1 (Mykytyn et al. 2002), the only
other known BBS2 paralog. To test this possibility, we
screened all exons and splice junctions of both splice
variants of BBS2L1 in patients from 84 independent
families of primarily European ancestry who had BBS.
Since complex inheritance has been demonstrated in
BBS, whereby mutations at more than one locus can be
necessary for pathogenesis (Katsanis et al. 2001a), we
did not preselect the family cohort on the basis of linkage
or mutational data from the other established loci.
We identified potentially pathogenic mutations in three
pedigrees. In pedigrees AR25 and AR395, we found a
homozygous H323R alteration in exon 10 that segre-
gated with the disorder (fig. 3A). In a third pedigree,
AR69, we detected a T211I homozygous alteration that
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also segregated with the disorder in both arms of the
family (fig. 3B), including individual –09, who is the
offspring of a consanguineous mating. Given these data,
we hypothesized that dysfunction of BBS2L1may cause
BBS, especially since, in addition to consistent segrega-
tion of each mutant allele with the disorder under a
Mendelian recessive model, neither change was found
in 192 ethnically matched control chromosomes.
The H323R change is predicted to affect local charge,
and the T211I alteration is likely to affect either hydro-
phobicity or the ability to form hydrogen bonds at this
residue. However, the paucity of functional data for the
protein left the formal possibility that these alterations
represent rare benign polymorphisms. Therefore, we ex-
amined genomewide genotypes generated at an ∼10-cM
resolution from nine consanguineous pedigrees of Saudi
Arabian origin, each of whom had been excluded from
harboring recessive mutations in all known loci by hap-
lotype and sequence analysis. In pedigree KK26, we iden-
tified a 15-cM region of homozygosity, on 4q26–q27, that
encompassed the BBS2L1 genomic locus. Performing
additional linkage studies, we established that only the
affected individual –05 was homozygous across a region
extending at least 2.6 cM proximally and 13 cM distal
to BBS2L1, and we derived a multipoint LOD score of
1.8 at for D4S408, which lies 2.6 cM prox-vp 0.001
imal to BBS2L1. Although not statistically significant
by itself, this LOD score peaked at the simulated the-
oretical maximum for this family, and, given our pre-
vious mutational data, we screened KK26 for BBS2L1.
We identified a homozygous 4-bp deletion that abolishes
the lysine at position 237 in exon 7 and which, by con-
ceptual translation, results in premature termination in
exon 9, at residue 296 (K237fsX296). This alteration
segregated with BBS in this family, as only the affected
individual, –05, was homozygous for the deletion (fig.
3A). The fact that this alteration eliminates nearly 65%
of the predicted protein, its absence from 288 control
chromosomes, including 96 chromosomes of normal,
unrelated Saudi individuals, and our previous muta-
tional data, we concluded that BBS2L1 represents a
novel BBS locus, which we term “BBS7.”
Potential Complex Inheritance in BBS7
Recent data support the existence of non-Mendelian
inheritance in some families with BBS, whereby three or
more mutant alleles at two loci either may be required
for pathogenesis (triallelic inheritance) or may modify
the phenotype (Katsanis et al. 2001a, 2002; Badano and
Katsanis 2002). The mutations we found in all four
BBS7 pedigrees satisfy the segregation criteria for a re-
cessive disorder. Nonetheless, we conducted genetic and
mutational analyses across the other four known BBS
genes to investigate the possibility that some families
with BBS7 mutations might also harbor pathogenic var-
iants at other loci. We found no additional pathogenic
alterations in families AR25, AR395, and KK26. In fam-
ily AR69, however, we detected an E234K alteration in
exon 8 of BBS1 that was present in all affected individ-
uals (fig. 3B). Although the functional significance of
this substitution cannot be assayed at present, the severe
structural consequences of this alteration and its absence
from 192 ethnically matched control chromosomes im-
ply that AR69 may harbor three pathogenic alleles. How-
ever, since no asymptomatic individuals have two mutant
BBS7 alleles, it is not possible to establish whether three
mutations are necessary in this family to cause the dis-
ease, whether a third mutation in BBS1 modifies the
phenotype, or whether the third mutation is only coin-
cidental. Nonetheless, our data indicate that, like BBS2,
BBS4, and BBS6, BBS7 may also interact genetically
with other loci to produce the BBS phenotype. A recent
evaluation of a small BBS1 patient cohort suggested that
mutations at this locus are inherited in an exclusively
recessive manner (Mykytyn et al. 2002). However, our
data indicate that BBS1 mutations might have a syn-
ergistic effect with BBS7, although evaluation of larger
patient cohorts will be required to test this hypothesis.
Domain Sharing between BBS1, BBS2, and BBS7
BBS7 exhibits similarity with a 252–amino acid region
of BBS2, between residues 147 and 398 (fig. 4). SMART
analyses (Schultz et al. 2000) of this region in BBS2 de-
tected a hypothetical structural classification of proteins
(SCOP) (Murzin et al. 1995; Lo Conte et al. 2002) do-
main that lies in the conserved area between residues
171–315 and is predicted to encode a six-bladed b-pro-
peller structure. Local alignment of BBS1, BBS2, and
BBS7 indicate that both BBS1 and BBS7 contain partially
overlapping portions of this SCOP domain (fig. 4a), rais-
ing the possibility that dysfunction of this module could
yield a common mechanism to the phenotype caused by
mutations at each locus.
Discussion
We report here the identification of the gene for BBS7,
which defines the seventh locus (the fifth one cloned) for
this disorder. Analysis of the BBS7 peptide sequence does
not offer any clues as to its cellular function, since it
neither resembles known molecules nor contains domains
of known function. However, comparison of BBS7 with
the other BBS proteins suggests a potential structural
link between BBS1, BBS2, and BBS7: a distinct substruc-
ture shared between the three molecules. Further anal-
yses of the human genomic sequence did not indicate
the presence of other proteins with this motif. Thus,
BBS1, BBS2, and BBS7 may belong to a distinct sub-
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family of proteins, mutations in any of which lead to
the same clinical entity. We detected by BLAST analysis
some similarity between this region and two members
of the integrin family (integrin 9 and 11) and the Esch-
erichia coli transcriptional regulator zraR (data not
shown). The biological significance of this observation
remains to be determined. Nevertheless, the identifica-
tion of this module is likely to be valuable in determining
the roles of these BBS proteins and their involvement in
the pathogenesis of this phenotype.
With the exception ofBBS1 andBBS2,which account
for 40% and 16% of BBS mutations, respectively (Bru-
ford et al. 1997; Katsanis et al. 1999; Beales et al. 2001),
the remaining BBS loci have a small contribution to BBS
(Beales et al. 2001; Katsanis et al. 2002). BBS7 is no
exception, since only 4 of 84 independent families carry
pathogenic alterations at this locus (3.5%), a frequency
similar to that of BBS4 (Katsanis et al. 2002). Our data
also indicate that ∼40% of our patients do not carry
mutations in any of the five known BBS genes. Although
the formal possibility exists that noncoding mutations
or genomic rearrangements may account for the re-
mainder of mutations, high-density haplotype analysis
across all seven loci has excluded ∼19%of our pedigrees
from carrying recessive mutations at any of these loci.
We therefore suggest that at least one more BBS locus
remains to be identified in the human genome.
Given the substantial genetic heterogeneity in BBS, it
is likely that identifying minor loci by traditional linkage
approaches will become increasingly difficult. In those
instances, domain-based computational approaches,
such as the one presented here or the evaluation of func-
tional candidate genes (such as BBS-interacting proteins,
for example), may prove to be a successful means of
identifying additional transcripts involved with this
disorder.
Genetic heterogeneity and clinical pleiotropy are also
potentially significant factors in modeling the transmis-
sion of the disease trait in BBS. From our data and pre-
vious studies, it appears that non-Mendelian inheritance
may sometimes exert an effect on all BBS genes cloned
to date, albeit at varying frequency. Of the four families
with BBS7 mutations, one family (AR69) segregates a
third, potentially pathogenic,BBS1 allele. However, since
none of the unaffected sibs are homozygous mutant for
BBS7, it is equally likely that the third mutant allele is
either required for pathogenesis or that it modifies the
phenotype. This genetic interaction between all BBS loci
potentially underlies a functional interaction, as dic-
tated by the principles of nonallelic noncomplementa-
tion (Badano and Katsanis 2002). The premise that
three of the BBS genes (BBS1, BBS2, and BBS7) encode
the same motif may even suggest that these proteins can
substitute for each other with varying degrees of effi-
ciency. Functional studies are required to investigate this
possibility, ascertain the effects of the alterations found
in patients, and establish why, in some instances, three
mutant alleles are required for pathogenesis.
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